Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, an oral substrate reduction therapy, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback